New S1P Receptor Modulator in Trials for Treatment of IBD

As more and more advances in science and medicine are made, we are seeing more promising drugs in the making for those with Crohn’s and Colitis. One of these is a new drug class called S1P receptor modulators. S1P stands for Sphingosine 1 phosphate. This is a bioactive mediator that is responsible for regulation of many cellular level processes by way of activation of a G protein family known as S1P receptors, or S1PRs. 

Since the finding of these, many in the medical field have had interest in what they do, and how they could potentially help inflammatory autoimmune diseases specifically. Through research, these processes have been found to be key regulators of lymphocyte migration. The thought process is that if they could block these lymphocytes, they could control migration to the intestines with IBD.

To be a little more specific, the S1P is a bioactive lipid modulator that regulates many cell functions including the intestinal inflammatory response and process. The S1P’s do this in many ways including; activation of T-cells and lymphocyte migration by way of vascular membranes in the circulatory system. These membranes contract and relax which also controls blood clotting as well as immune function. These are all very complex interactions and more research needs to be done, but the S1P receptor modulator holds promising value for IBD.      

The interaction of this S1P/ S1P1 axis has great potential as an upcoming treatment. The strategy of modulating lymphocytes is quite contrary to many current treatment options. While many options now use antibody inhibition by modulating memory T-cells as well as T-cells responsible for intestinal mucosa, which can only be done through heavy immunomodulation, S1P receptor modulators affect the secondary lymphoid tissues not affecting the T-cells. This revolutionary possible new treatment brings hope to those battling IBD as one of the new prospects for treatment appearing on the horizon. Keep your eye out for this drug class as a new possible treatment in the coming years. 

Want to check out all the scientific details for yourself? Read the original publishing’s HERE!  

Note: * This is NOT an affiliate post. I do not receive anything for promoting or recommending products or services. *Â